Diacerein reduces inflammasome activation and SARS-CoV-2 virus replication: a proof-of-concept translational study

BackgroundSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is linked to high mortality, primarily through an intense inflammatory response. Diacerein has emerged as a potential therapy for COVID-19 due to its potential impact in decreasing the inflammasome activation and coronavirus repl...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Helison R. P. Carmo, Alejandro Rossel Castillo, Isabella Bonilha, Erica I. L. Gomes, Joaquim Barreto, Filipe A. Moura, Gustavo Gastão Davanzo, Lauar de Brito Monteiro, Stéfanie Primon Muraro, Gabriela Fabiano de Souza, Joseane Morari, Flávia Elisa Galdino, Natália S. Brunetti, Guilherme Reis-de-Oliveira, Victor Corasolla Carregari, Wilson Nadruz, Daniel Martins-de-Souza, Alessandro S. Farias, Licio A. Velloso, José Luiz Proenca-Modena, Marcelo A. Mori, Watson Loh, Deepak L. Bhatt, Derek M. Yellon, Sean M. Davidson, Pedro G. De Oliveira, Pedro M. Moraes-Vieira, Andrei C. Sposito
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	Frontiers Media S.A. 2024-10-01
سلاسل:	Frontiers in Pharmacology
الموضوعات:	COVID-19 diacerein rhein pre-clinical clinical trial
الوصول للمادة أونلاين:	https://www.frontiersin.org/articles/10.3389/fphar.2024.1402032/full
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!